Please login to the form below

Not currently logged in
Email:
Password:

Mavenclad

This page shows the latest Mavenclad news and features for those working in and with pharma, biotech and healthcare.

Dupixent gains can’t keep Sanofi on a growth track

Dupixent gains can’t keep Sanofi on a growth track

despite greater competition from drugs like Roche’s Ocrevus (ocrelizumab), Novartis’ Mayzent (siponimod) and Merck KGaA’s Mavenclad (cladribine).

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    The Accelerated Access Collaborative. Ewan Barbour, Market Access and Pricing Director, Merck, presented on its multiple sclerosis treatment Mavenclad being selected to be among the first designated Rapid Uptake products on ... Ewan Barbour. He said the

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    The company has just secured 'Rapid Uptake' status for its multiple sclerosis drug Mavenclad via the new Accelerated Access Collaborative process.

  • Tackling a formidable foe Tackling a formidable foe

    MAVENCLAD offers lasting control of the disease allowing them to plan for pregnancy once the treatment course is completed. ... MAVENCLAD’S short-course oral therapy profile is a bonus to a condition freighted with psychological drag-weights.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics